Noah Chisamore
Doctorate Student / Research Assistant at the University of Toronto
Data updated
Research Footprint
Noah Chisamore appears in 7 tracked papers (2021–2026), most studied alongside Ketamine, Psilocybin and Ayahuasca, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Anxiety Disorders.
Most-cited paper: Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic (24 citations).
Frequent co-authors: Jonathan Rosenblat, Roger McIntyre and Shokouh Meshkat.
Background & Research
Noah Chisamore is a doctoral student and research assistant affiliated with the University of Toronto and the University Health Network in Toronto. His published work focuses on psychedelic-assisted psychotherapy and ketamine-related interventions for depression, including systematic reviews and clinical outcomes research. He has presented on psilocybin-assisted psychotherapy at the University of Toronto Department of Pharmacology and Toxicology.
Key Impact
He contributes to clinical and review research on psilocybin-assisted psychotherapy and ketamine for treatment-resistant depression, including pediatric and real-world effectiveness studies.
Collaboration Network
18 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Noah Chisamore is associated with.
University of Toronto
University of Toronto is a leading Canadian research university whose psychedelic and psychiatric research spans the Department of Psychiatry, University Health Network collaborations, and specialized clinical units including mood-disorders psychopharmacology programs.
View stakeholder →University of Toronto Mississauga
academicThe Psychedelic Studies Research Program (PSRP) distinguishes itself by adhering strictly to the principles of Open Science, pre-registering their analysis plans, and making their data and protocols freely accessible. A primary focus for the team at the PSRP is the clinical study of microdosing. Led by Dr. Norman Farb, the program conducts double-blind, randomized controlled trials investigating the benefits and drawbacks of microdosing very low doses of psilocybin.
View stakeholder →Brain and Cognition Discovery Foundation
Non-ProfitCanada-based foundation backing translational and clinical research programs in mental health, including psychedelic-relevant workstreams.
View stakeholder →